CN107648282A - Application of the Antrodia camphorata in preventing and treating myocardial hypertrophy and myocardial fibrosis - Google Patents
Application of the Antrodia camphorata in preventing and treating myocardial hypertrophy and myocardial fibrosis Download PDFInfo
- Publication number
- CN107648282A CN107648282A CN201610594774.0A CN201610594774A CN107648282A CN 107648282 A CN107648282 A CN 107648282A CN 201610594774 A CN201610594774 A CN 201610594774A CN 107648282 A CN107648282 A CN 107648282A
- Authority
- CN
- China
- Prior art keywords
- myocardial
- caused
- fibrosis
- myocardial fibrosis
- hypertrophy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses application of the Antrodia camphorata in preventing and treating myocardial hypertrophy and myocardial fibrosis.Application provided by the present invention is specially application of the fruiting body extract of Antrodia camphorata or Antrodia camphorata in following (A) or (B)：(A) product for preventing and/or treating myocardial hypertrophy and/or myocardial fibrosis is prepared；(B) prevent and/or treat myocardial hypertrophy and/or myocardial fibrosis.Antrodia camphorata enables to the body heart weight ratio caused by myocardial hypertrophy and heart shin bone, and than raising, in cardiac muscular tissue, the expression of ANF genes is raised and is effectively suppressed；So that the body myocardial collagen fraction by volume rise caused by myocardial fibrosis, cardiac muscular tissue myocardial fibrosis marker gene Collagen1 and Collagen3 expression rise are also effectively suppressed.It can be seen that Antrodia camphorata plays an important roll for preventing and treating myocardial hypertrophy and myocardial fibrosis.
Description
Technical field
The invention belongs to biomedicine field, is related to a kind of new application of Antrodia camphorata, specially Antrodia camphorata is in preventing and treating cardiac muscle
Application in loose and myocardial fibrosis.
Background technology
When acute and chronic haemodynamics excess load, the knot of adaptability can occur for the normal blood circulation of maintenance, heart
Structure is reconstructed, and it includes the reconstruction of cardiac muscle cell and interstitial.Because cardiac muscle cell is a kind of terminally differentiated cells, therefore myocyte increases
It is the main forms of myocardial structural reconstruction, this is a kind of strong compensatory form, but it is not unlimited, if
The cause of disease can not be for a long time eliminated, then the function of Hypertrophic Cardiac just can not remain normal for a long time and turn to heart failure eventually.It is chronic
Heart failure is typically all the gradual occurrence and development on the basis of myocardium compensatory hypertrophy.
Myocardial fibrosis (myocardial fibrosis), also known as cardia calcification, it is into fiber with cardiac muscular tissue's interstitial
The reconstruct for the cardiac mesenchymal that cell hyperproliferation, collagenous fibres excess deposition and spatial abnormal feature are characterized.To weight in being due to more
The coronary atherosclerotic of degree is narrow to cause cardiac muscle cell's continuation and (or) the myocardial ischemia-anoxemia aggravated repeatedly to be produced
Raw result, cause the ischemic heart disease (ischemic heart disease, IHD) for gradually developing into heart failure, i.e.,
Chronic ischemic heart disease (chronic ischemic heart disease).
Cardiac muscle cell is a kind of well differentiated thesocyte, excessive in long-term pressure and/or volumetric loading, body fluid because
Under the pathological states such as element stimulation, cardiac myocytic phenotype changes, volume increase, while can also have myocardial interstitial cells propagation.
Myocardial hypertrophy produces slower but strong compensatory form as a kind of, strengthens myocardial contractive power, is maintained heart
Normal blood circulation, while have suitable reserve capabillity.But this compensation long-term existence also has its disadvantage, mainly
Show that myocardial hypertrophy is a kind of unbalanced growth pattern, increase degree and arteriole and the blood capillary in cardiac muscle of myocardial volume
The growth of pipe and the growth of sympathetic neuron aixs cylinder mismatch, and the intensive and vessel density degree of sympathetic innervation shows in heart
Write and be less than normally, therefore Hypertrophic Cardiac is in anaerobic condition, enable amount generation deficiency often in load increase, cardiac contractility subtracts
It is weak.In addition, in the state of long-term pressure and/or volumetric loading is excessive, feritin-angiotensiri system
The activation of system (RASS) makes Angiotensin II (ANG-II) and aldosterone abnormal increase downstream, and Angiotensin II can be with
Promote Proliferation of Cardiac Fibroblasts and raise the expression of collagen gene；There are some researches show aldosterone can with dose-dependant
Collage synthesis being stimulated, and this effect can be by its inhibitor --- spirolactone reverses.Aldosterone can also cause endothelium work(
Energy obstacle, while promote the remodeling of cardiac muscle and vascular smooth muscle, cause ventricle and blood vessel stiff, loose, fibrosis occurs for cardiac muscle
And necrosis, damage cardiac function.Excessive Collagen fiber deposition ultimately results in cardiac fibrosis, and ventricle wall compliance declines, and relaxes
Zhang Gongneng is damaged, and function gradually moves towards decompensation by compensatory.
At present, clinically beta-blocker is included for myocardial hypertrophy and the most important treatment method of myocardial fibrosis
With angiotensin converting enzyme inhibitors (ACEI).
Beta-blocker can antagonism sympathetic activity, reducing heart rate, reduce myocardial oxygen consumption, suppress high concentration
Direct toxic action of the catecholamine to cardiac muscle；But low blood pressure may be caused, induced because suppressing beta 2 receptor or aggravate branch
San bronchial asthma, atrioventricular block is aggravated, and unexpected drug withdrawal often makes original exacerbation of symptoms after long-term use.
ACEI classes medicine mainly suppresses ACE activity, reduces the generation of angiotensins (Ang-II), reduces bradykinin
Hydrolysis, causes vasodilation, hypovolemia, drop in blood pressure, and is unequivocally established and can mitigate the effect of Hypertensive disease.But
It is due to that ACEI class medicines cause the bradykinin or other vasoactive peptides (such as Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2) that second messenger is served as in cough reflex
Increase and cause excitant dry cough to be the main reason for many patients can not be resistant to ACEI, although a variety of methods are used to eliminate ACEI
Caused cough, but can seldom obtain lasting effect.ACEI can also cause angioedema.
Existing research shows that Antrodia camphorata has antitumor, anti-inflammatory and anti-oxidant etc. pharmacological activity.Researcher
It was found that Antrodia camphorata antineoplastic action mechanism improve Fas/APO-1 expression and ubiquitin memebrane protein in p53 paths with it, can
The content of dissolubility ubiquitin part and the expression of regulation Bcl-2 family proteins, so as to promote the apoptosis of mitochondria pathway relevant；Anti-inflammatory
It is relevant that mechanism with it suppresses the phosphorylation of extracellular signal-regulated kinase system and JNK signal transduction systems；It is and anti-oxidant
The gst enzyme in liver is raised with it, the ratio of oxidized form and reduced glutathione is maintained, scavenging activated oxygen, reduces
Lipid peroxidation is relevant.The fructification of Antrodia camphorata and mycelial extract include polysaccharide, steroidal, triterpenes and benzene class
Compound.
So far, there has been no be used to Antrodia camphorata study treatment myocardial hypertrophy and the relevant report of myocardial fibrosis.
The content of the invention
It is an object of the invention to provide a kind of new application of Antrodia camphorata,
New application provided by the present invention is specially the fruiting body extract of Antrodia camphorata or Antrodia camphorata at following (A) or (B)
In application：
(A) product for preventing and/or treating myocardial hypertrophy and/or myocardial fibrosis is prepared；
(B) prevent and/or treat myocardial hypertrophy and/or myocardial fibrosis.
More specifically, for it is following it is any in application：
(a) prepare for suppressing the body heart weight ratio caused by myocardial hypertrophy and/or heart shin bone than elevated
Product, or suppress the body heart weight ratio caused by myocardial hypertrophy and/or heart shin bone than rise；
(b) prepare for suppress due to ANF genes in body cardiac muscular tissue caused by myocardial hypertrophy expression (such as
MRNA expressions) elevated product, or suppress due to the expression water of ANF genes in body cardiac muscular tissue caused by myocardial hypertrophy
Flat (such as mRNA expressions) rise；
(c) prepare for suppression elevated product of body myocardial collagen fraction by volume caused by myocardial fibrosis, or
Suppress the body myocardial collagen fraction by volume caused by myocardial fibrosis to raise；
(d) prepare for suppressing the body cardiac muscular tissue myocardial fibrosis marker gene caused by myocardial fibrosis
Expression (such as mRNA expressions) elevated product, or suppress the body cardiac muscular tissue center caused by myocardial fibrosis
Expression (such as mRNA expressions) rise of myofibrosis marker gene.
Accordingly, the thing of the material containing Antrodia camphorata or the fruiting body extract containing Antrodia camphorata is also claimed in the present invention
Matter it is following it is any in application：
(A) product for preventing and/or treating myocardial hypertrophy and/or myocardial fibrosis is prepared；
(B) prevent and/or treat myocardial hypertrophy and/or myocardial fibrosis；
(a) prepare for suppressing the body heart weight ratio caused by myocardial hypertrophy and/or heart shin bone than elevated
Product, or suppress the body heart weight ratio caused by myocardial hypertrophy and/or heart shin bone than rise；
(b) prepare for suppress due to ANF genes in body cardiac muscular tissue caused by myocardial hypertrophy expression (such as
MRNA expressions) elevated product, or suppress due to the expression water of ANF genes in body cardiac muscular tissue caused by myocardial hypertrophy
Flat (such as mRNA expressions) rise；
(c) prepare for suppression elevated product of body myocardial collagen fraction by volume caused by myocardial fibrosis, or
Suppress the body myocardial collagen fraction by volume caused by myocardial fibrosis to raise；
(d) prepare for suppressing the body cardiac muscular tissue myocardial fibrosis marker gene caused by myocardial fibrosis
Expression (such as mRNA expressions) elevated product, or suppress the body cardiac muscular tissue center caused by myocardial fibrosis
Expression (such as mRNA expressions) rise of myofibrosis marker gene.
Accordingly, a kind of product is also claimed in the present invention, and its active component is the fructification of Antrodia camphorata and/or Antrodia camphorata
Extract；The product has at least one of following function：
(a1) prevent and/or treat myocardial hypertrophy and/or myocardial fibrosis；
(a2) suppress the body heart weight ratio caused by myocardial hypertrophy and/or heart shin bone than rise；
(a3) suppress due to expression (such as mRNA expression of ANF genes in body cardiac muscular tissue caused by myocardial hypertrophy
It is horizontal) rise；
(a4) suppress the body myocardial collagen fraction by volume caused by myocardial fibrosis to raise；
(a5) the expression water of the body cardiac muscular tissue myocardial fibrosis marker gene caused by myocardial fibrosis is suppressed
Flat (such as mRNA expressions) rise.
In the present invention, suppression body myocardial collagen fraction by volume caused by myocardial fibrosis raises specific body
It is now the liter for the sirius red stains Myocardial collagen volume fraction for suppressing the body cardiac muscular tissue caused by myocardial fibrosis
It is high.
Further, in the present invention, the myocardial fibrosis marker gene be specially the genes of Collagen 1 and/or
The genes of Collagen 3.
In the present invention, the ANF genes be specially GenBank be NM_008725 shown in gene (Up date：
2015-10-26)；The genes of Collagen 1 be specially GenBank be NM_007742 shown in gene (Up date：2015-11-
18)；The genes of Collagen 3 be specially GenBank be NM_009930 shown in gene (Up date：2015-11-25).
In the present invention, the heart weight ratio is cardiac weight and the ratio of body weight；The heart shin bone ratio is heart
The ratio of weight and tibia length.
In the present invention, the body is specially mouse (more specific such as BALB/c mouse).Accordingly, the cardiac muscle fertilizer
Big is specially because the mouse cardiac muscle of isoprel (ISO) induction is loose；The myocardial fibrosis is specially due to isopropyl
The mouse cardiac muscle fibrosis of adrenaline (ISO) induction.
Wherein, the product can be medicine.
In the present invention, the fruiting body extract (AC) of the Antrodia camphorata is the ethanol extract of Antrodia camphorata fructification.Its
In, the concentration of ethanol is 95% (volumn concentration, solvent are water).The fruiting body extract (AC) of the Antrodia camphorata is by ox
Antrodia fructification is first broken into coarse powder, is adding 95% ethanol heating and refluxing extraction, is repeating extraction 4 times, merging extract solution, is filtering,
Be concentrated under reduced pressure to obtain total extract.Specifically can be according to " Xue Qiao, Qi Wang, Shuai Jia, et al.Metabolites
identification and multi-component pharmacokinetics ofergostane and lanostane
triterpenoids in the anticancer mushroomAntrodia cinnamomea.Journal of
It is prepared by the method described in Pharmaceutical and Biomedical Analysis 111 (2015) 266-276 " texts
Obtain.
In an embodiment of the present invention, the dosage of the fruiting body extract (AC) of the Antrodia camphorata is about 500mg/kg bodies
Weight.
The present invention is it is demonstrated experimentally that the fruiting body extract (AC) of Antrodia camphorata enables to the body caused by myocardial hypertrophy
Heart weight ratio and heart shin bone raise than the mRNA expressions of ANF genes in rise, cardiac muscular tissue, are effectively pressed down
System；So that the rise of myocardial collagen fraction by volume, cardiac muscular tissue's myocardial fibrosis marker gene caused by myocardial fibrosis
The expression rise of (such as Collagen1 genes and Collagen3 genes), is also effectively suppressed.Thus it is clear that Antrodia camphorata and
Its fruiting body extract plays an important roll for preventing and treating myocardial hypertrophy and myocardial fibrosis.
Further, with clinically blocking at present for myocardial hypertrophy and the most important medicine beta receptor of myocardial fibrosis
Agent is compared with angiotensin converting enzyme inhibitors (ACEI), present invention discover that the fruiting body extract (AC) of Antrodia camphorata can show
The suppression myocardial hypertrophy of work, and the result of cardiac ultrasonic displays that it can't suppress heart function, conversely, fetus can also be lowered
Gene A NF mRNA expressions, heart function can be obviously improved by showing the fruiting body extract (AC) of Antrodia camphorata.In addition,
In the experiment of the fruiting body extract (AC) of Antrodia camphorata, there is not the symptom of excitant dry cough, and cause due to myocardium fine
Caused by dimensionization myocardial collagen fraction by volume rise, cardiac muscular tissue's myocardial fibrosis marker gene (such as Collagen1 genes and
Collagen3 genes) expression rise, be also effectively suppressed.
It can be seen that Antrodia camphorata and its fruiting body extract have larger answer in the preventing and treating to myocardial hypertrophy and myocardial fibrosis
Use prospect.
Brief description of the drawings
Fig. 1 is that when heart shin compares result to mouse core body.Wherein, A is heart body ratio；B is heart shin ratio.**P<0.01, * * * P<
0.001, n=5.
Fig. 2 is mouse heart paraffin section sirius red stains (figure A) and quantitative (figure B) result.Wherein, A is Sirius
Red colouring result；B is fibrosis (myocardial collagen fraction by volume) quantitative result.*P<0.05, n=5.
Fig. 3 is the Realtime PCR knots of murine myocardium Collagen 1, Collagen 3 and tri- genes of ANF
Fruit.Wherein, A is the Realtime PCR results of the genes of Collagen 1；B is that the Realtime PCR of the genes of Collagen 3 are tied
Fruit；C is the Realtime PCR results of ANF genes.*P<0.05, * * P<0.01, n=5.
Embodiment
Experimental method used in following embodiments is conventional method unless otherwise specified.
Material used, reagent etc., unless otherwise specified, are commercially obtained in following embodiments.
Antrodia camphorata：It is recorded in " Xue Qiao, Qi Wang, Shuai Jia, et al.Metabolites
identification and multi-component pharmacokinetics ofergostane and lanostane
triterpenoids in the anticancer mushroomAntrodia cinnamomea.Journal of
The texts of Pharmaceutical and Biomedical Analysis 111 (2015) 266-276 " one, the public can be at applicant
Obtain, the experiment that can only be used to repeat the present invention uses.
The fruiting body extract (abbreviation AC) of Antrodia camphorata：Specific preparation method referring to " Xue Qiaoa, Qi Wanga,
Shuai Jia,et al.Metabolites identification and multi-component
pharmacokinetics ofergostane and lanostane triterpenoids in the anticancer
mushroomAntrodia cinnamomea.Journal of Pharmaceutical and Biomedical Analysis
The text of 111 (2015) 266-276 " one.
The mouse cardiac muscle that embodiment 1, the fruiting body extract (AC) of Antrodia camphorata are induced isoprel (ISO) is loose
And myocardial fibrosis protective effect experiment
First, the mouse cardiac muscle hypertrophy of isoprel (ISO) induction and the preparation of myocardial fibrosis model
The male BALB/c mouse (Si Beifu (Beijing) Bioisystech Co., Ltd) of 10 week old, weight average 25g, use
The big common breeding feed of mouse (Military Medical Science Institute's Experimental Animal Center) feeding, while give mouse back hypodermic injection
ISO (5mg/kg/d, i.e., mouse injection ISO 5mg per kg body weight per day), continuous modeling in 7 days, while give 0.5%
The μ L of (0.5g/100ml) sodium carboxymethylcellulose (CMC-Na) 200 (200 μ L are the daily dosages of every mouse) gavage, is obtained different
The mouse cardiac muscle hypertrophy and myocardial fibrosis model of third adrenaline (ISO) induction.
2nd, the mouse cardiac muscle hypertrophy and the heart that the fruiting body extract (AC) of Antrodia camphorata is induced isoprel (ISO)
Myofibrosis protective effect is studied
1st, experiment packet and processing
The preparation of 0.5%CMC-Na containing AC：The AC of certain mass is weighed, ultrasonic dissolution makes AC in 0.5%CMC-Na
Concentration is 50mg/mL.
Experimental group (ISO+AC) is administered：The mouse core of isoprel (ISO) induction is prepared using the method for step 1
Myohypertrophia and myocardial fibrosis mouse model, and since the modeling, that gives that the above prepares simultaneously to modeling mouse contains
There is AC 0.5%CMC-Na, (equivalent about 500mg/kg body weight/days, wherein 500mg refer to every μ L of mouse stomach 200 daily
It is AC quality), it is so continuous 7 days.
Control group (ISO) is administered：The mouse cardiac muscle fertilizer of isoprel (ISO) induction is prepared using the method for step 1
Big and myocardial fibrosis mouse model, and since the modeling, 0.5%CMC-Na is given to modeling mouse, daily to every
Mouse stomach 200 μ L, it is so continuous 7 days.
Negative control group (NS)：Normally the male BALB/c mouse without any processing uses the common breeding feed of big mouse
Simultaneously, daily every mouse stomach 0.5%CMC-Na 200 μ L are so continuous 7 days for feeding.
2nd, animal puts to death materials
Each group mouse before the 8th day puts to death, weigh before execution, plucks eyeball and takes blood, then carries out the heart to mouse with PBS by mouse
Dirty perfusion wash.Complete separating mouse heart, weighs heart gross weight.Leave and take same site heart and carry out morphologic detection, leave and take
- 80 DEG C of preservations of another part heart tissue, to be ready for use on real-time quantitative Realtime PCR (Realtime PCR) detections.Together
When, the leg shin bone of mouse two is left and taken, is measured using slide measure.
3rd, Testing index
(1) mouse core body ratio and heart shin ratio
According to put to death in step 2 weigh before mouse, put to death after alleged heart gross weight, and surveyed using slide measure
The tibia length of amount, calculate heart weight ratio (abbreviation heart body ratio, i.e. heart weight and the mass ratio of body weight, the unit of each group mouse
For mg/g) and heart shin bone ratio (abbreviation heart shin ratio, the i.e. ratio of cardiac weight and tibia length, unit mg/mm).
(2) murine myocardium paraffin section sirius red stains and quantitative
Heart tissue for morphologic detection carries out standard Picro-Sirius red dye by Peking University's angiocarpy institute's morphology room
Color, the fibrosis that coloration result carries out cardiac muscular tissue using Image J softwares quantify.
(3) mouse heart RNA extractions and Realtime PCR detect ANF genes and myocardial fibrosis mark in cardiac muscular tissue
Will gene C ollagen 1 and Collagen 3 expression
Wherein, the ANF genes be specially GenBank be NM_008725 shown in gene (Up date：2015-10-
26)；The genes of Collagen 1 be specially GenBank be NM_007742 shown in gene (Up date：2015-11-18)；
The genes of Collagen 3 be specially GenBank be NM_009930 shown in gene (Up date：2015-11-25).
Mouse heart RNA is extracted and specific Realtime PCR detection methods are as follows：
The mouse heart of -80 DEG C of preservations of sub-fraction is taken, tissue is taken out with apparatus of the sterilization without RNase, rapidly in precooling
PBS in rinse well, be fitted into centrifuge tube and be placed in liquid nitrogen.Trizol is added in homogenate tube, the tissue institute per 50-100mg
Need Trizol 1mL.Tissue takes out from liquid nitrogen, pours into immediately in the homogenate tube equipped with Trizol, is homogenized.The sample after homogenate
Product are moved into clean centrifuge tube, are stored at room temperature 5 minutes.4 DEG C of 12000rpm are centrifuged 10 minutes, take supernatant to new centrifuge tube
In.Often pipe adds the 200 fresh chloroforms of μ L (being put into refrigerator in advance), is acutely shaken 15 seconds, is stored at room temperature 3 minutes with hand.4℃
12000rpm is centrifuged 15 minutes.
Now liquid is divided into three layers, careful to draw supernatant liquid and be transferred in new centrifuge tube, is careful not to be drawn onto boundary
The DNA and protein of face phase.Often pipe addition and the isometric fresh isopropanol of supernatant, overturn and mix, be stored at room temperature 10 points repeatedly
Clock.4 DEG C of 12000rpm are centrifuged 15 minutes.Now visible ttom of pipe has white plates precipitation.Supernatant is discarded, add precooling uses DEPC
75% ethanol 1mL of water configuration is washed, and vortex hangs precipitation.4 DEG C of 7500rpm centrifuge 5-10 minutes.Carefully outwell
Layer liquid (ethanol).
The careful ethanol for sopping up remnants, stand on ice until ethanol volatilization completely is clean.Add proper volume (20-50 μ L)
DEPC water dissolving RNA, the RNA of indissoluble can be placed in 55 DEG C of water-baths 5 minutes.Distinguished using RNA electrophoresis and ultraviolet specrophotometer
Detect RNA quality and abundance.The loading system provided according to EvaGreen qPCR MasterMix (Canadian abm companies)
Carry out real-time quantitative RT-PCR.
Wherein, it is as follows for detecting the primer sequence of ANF genes：
ANF-F：5’-GCTTCCAGGCCATATTGGAG-3’；
ANF-R：5’-GGGGGCATGACCTCATCTT-3’.
Primer sequence for detecting myocardial fibrosis marker gene Collagen 1 is as follows：
Collagen 1-F：5’-GCTCCTCTTAGGGGCCACT-3’；
Collagen 1-R：5’-CCACGTCTCACCATTGGGG-3’.
Primer sequence for detecting myocardial fibrosis marker gene Collagen 3 is as follows：
Collagen 3-F：5’-CTGTAACATGGAAACTGGGGAAA-3’；
Collagen 3-R：5’-CCATAGCTGAACTGAAAACCACC-3’.
Using β-actin as internal reference, the primer sequence for detecting internal reference is as follows：
β-actin-F：5’-GGCTGTATTCCCCTCCATCG-3’；
β-actin-R：5’-CCAGTTGGTAACAATGCCATGT-3’.
4th, testing result
(1) mouse core body ratio and heart shin ratio
As a result it is as shown in Figure 1.As seen from the figure, compared with negative control group (NS), administration control group (ISO) mouse
Heart body ratio and heart shin ratio significantly raise (P<0.001 or P<0.01).But compared with administration control group (ISO), administration experiment
The heart body ratio and heart shin ratio of group (ISO+AC) mouse significantly reduce (P<0.01).The result is visible：AC can significantly inhibit ISO
Caused mouse core body shows that AC has notable protective effect to myocardial hypertrophy caused by ISO than the rise with heart shin ratio.
(2) fibrosis of murine myocardium
As a result it is as shown in Figure 2.As seen from the figure, compared with negative control group (NS), administration control group (ISO) mouse
Heart paraffin section sirius red stains myocardial collagen fraction by volume significantly raises (P<0.05).But with control group is administered
(ISO) compare, the heart paraffin section sirius red stains myocardial collagen fraction by volume of administration experimental group (ISO+AC) mouse shows
Writing reduces (P<0.05).The result is visible：AC can significantly reduce mouse heart sirius red stains caused by ISO, show AC
There is notable protective effect to myocardial fibrosis caused by ISO.
(3) ANF genes and myocardial fibrosis marker gene Collagen 1 and Collagen 3 in murine myocardium
Expression
As a result it is as shown in Figure 3.As seen from the figure, compared with negative control group (NS), administration control group (ISO) mouse
Cardiac muscular tissue myocardial fibrosis marker gene Collagen 1 and Collagen 3 expression significantly raises (P<0.01).
But compared with administration control group (ISO), cardiac muscular tissue's myocardial fibrosis mark base of experimental group (ISO+AC) mouse is administered
Because Collagen 1 and Collagen 3 expression significantly reduce (P<0.05).In addition, compared with negative control group (NS),
The expression that ANF genes in the cardiac muscular tissue of control group (ISO) mouse are administered significantly raises (P<0.01).But with administration
Control group (ISO) is compared, and the level that reaches of the ANF genes of experimental group (ISO+AC) mouse is administered and significantly reduces (P<0.01).The knot
Fruit is visible：AC can significantly inhibit mouse cardiac muscle markers of fibrosis gene C ollagen 1 and Collagen 3 caused by ISO
Expression rise, shows that AC has notable protective effect to myocardial fibrosis caused by ISO.Meanwhile AC can significantly inhibit ISO and draw
The murine myocardium fetus Gene A NF risen expression rise, show that there is AC significantly protection to make to myocardial hypertrophy caused by ISO
With.
Claims (7)
1. application of the fruiting body extract of Antrodia camphorata or Antrodia camphorata in following (A) or (B)：
(A) product for preventing and/or treating myocardial hypertrophy and/or myocardial fibrosis is prepared；
(B) prevent and/or treat myocardial hypertrophy and/or myocardial fibrosis.
2. the fruiting body extract of Antrodia camphorata or Antrodia camphorata it is following it is any in application：
(a) prepare for suppressing the body heart weight ratio caused by myocardial hypertrophy and/or heart shin bone than elevated product,
Or suppress the body heart weight ratio caused by myocardial hypertrophy and/or heart shin bone than rise；
(b) prepare for suppressing due to the elevated production of expression of ANF genes in body cardiac muscular tissue caused by myocardial hypertrophy
Product, or suppress due to the expression rise of ANF genes in body cardiac muscular tissue caused by myocardial hypertrophy；
(c) prepare for suppressing the elevated product of body myocardial collagen fraction by volume caused by myocardial fibrosis, or suppression
The body myocardial collagen fraction by volume caused by myocardial fibrosis raises；
(d) expression for suppressing the body cardiac muscular tissue myocardial fibrosis marker gene caused by myocardial fibrosis is prepared
Horizontal elevated product, or suppress the table of the body cardiac muscular tissue myocardial fibrosis marker gene caused by myocardial fibrosis
Raised up to level.
3. the material of the material containing Antrodia camphorata or the fruiting body extract containing Antrodia camphorata it is following it is any in application：
(A) product for preventing and/or treating myocardial hypertrophy and/or myocardial fibrosis is prepared；
(B) prevent and/or treat myocardial hypertrophy and/or myocardial fibrosis；
(a) prepare for suppressing the body heart weight ratio caused by myocardial hypertrophy and/or heart shin bone than elevated product,
Or suppress the body heart weight ratio caused by myocardial hypertrophy and/or heart shin bone than rise；
(b) prepare for suppressing due to the elevated production of expression of ANF genes in body cardiac muscular tissue caused by myocardial hypertrophy
Product, or suppress due to the expression rise of ANF genes in body cardiac muscular tissue caused by myocardial hypertrophy；
(c) prepare for suppressing the elevated product of body myocardial collagen fraction by volume caused by myocardial fibrosis, or suppression
The body myocardial collagen fraction by volume caused by myocardial fibrosis raises；
(d) expression for suppressing the body cardiac muscular tissue myocardial fibrosis marker gene caused by myocardial fibrosis is prepared
Horizontal elevated product, or suppress the table of the body cardiac muscular tissue myocardial fibrosis marker gene caused by myocardial fibrosis
Raised up to level.
4. a kind of product, its active component is the fruiting body extract of Antrodia camphorata and/or Antrodia camphorata；The product has following work(
At least one of can：
(a1) prevent and/or treat myocardial hypertrophy and/or myocardial fibrosis；
(a2) suppress the body heart weight ratio caused by myocardial hypertrophy and/or heart shin bone than rise；
(a3) suppress due to the expression rise of ANF genes in body cardiac muscular tissue caused by myocardial hypertrophy；
(a4) suppress the body myocardial collagen fraction by volume caused by myocardial fibrosis to raise；
(a5) the expression liter of the body cardiac muscular tissue myocardial fibrosis marker gene caused by myocardial fibrosis is suppressed
It is high.
5. the product described in application or claim 4 according to Claims 2 or 3, it is characterised in that：The cardiac muscle fibre
It is the genes of Collagen 1 and/or the genes of Collagen 3 to change marker gene.
6. according to any described application or product in claim 2-5, it is characterised in that：The body is mouse；The heart
Myohypertrophia is because the mouse cardiac muscle of isoprel induction is loose；The myocardial fibrosis is because isoprel lures
The mouse cardiac muscle fibrosis led.
7. according to any described application or product in claim 1-6, it is characterised in that：The product is medicine.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610594774.0A CN107648282A (en) | 2016-07-26 | 2016-07-26 | Application of the Antrodia camphorata in preventing and treating myocardial hypertrophy and myocardial fibrosis |
| TW106100633A TWI629991B (en) | 2016-07-26 | 2017-01-09 | Antrodia cinnamomea in the prevention and treatment of myocardial hypertrophy and myocardial fibrosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610594774.0A CN107648282A (en) | 2016-07-26 | 2016-07-26 | Application of the Antrodia camphorata in preventing and treating myocardial hypertrophy and myocardial fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107648282A true CN107648282A (en) | 2018-02-02 |
Family
ID=61126431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610594774.0A Pending CN107648282A (en) | 2016-07-26 | 2016-07-26 | Application of the Antrodia camphorata in preventing and treating myocardial hypertrophy and myocardial fibrosis |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN107648282A (en) |
| TW (1) | TWI629991B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021218974A1 (en) * | 2020-04-28 | 2021-11-04 | Alps Biotech Co., Ltd. | Uses of antrodia cinnamomea extract in manufacturing products for reducing expression and treating associated diseases of angiotensin converting enzyme 2 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104220083A (en) * | 2012-03-26 | 2014-12-17 | 国鼎生物科技股份有限公司 | Methods and compositions for treating arteriosclerotic vascular diseases |
| US20150050315A1 (en) * | 2013-08-13 | 2015-02-19 | Industrial Technology Research Institute | Method for modulating th17 cells and method for treating a disease related to modulation of th17 cells |
| CN104367600A (en) * | 2013-08-13 | 2015-02-25 | 财团法人工业技术研究院 | Application of Antrodia camphorata extract in preparing medicine for regulating Th17 cells or treating diseases related to Th17 cell regulation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI622406B (en) * | 2013-10-23 | 2018-05-01 | 善笙生物科技股份有限公司 | Uses of compounds and mixtures from antrodia cinnamomea mycelia |
-
2016
- 2016-07-26 CN CN201610594774.0A patent/CN107648282A/en active Pending
-
2017
- 2017-01-09 TW TW106100633A patent/TWI629991B/en not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104220083A (en) * | 2012-03-26 | 2014-12-17 | 国鼎生物科技股份有限公司 | Methods and compositions for treating arteriosclerotic vascular diseases |
| US20150050315A1 (en) * | 2013-08-13 | 2015-02-19 | Industrial Technology Research Institute | Method for modulating th17 cells and method for treating a disease related to modulation of th17 cells |
| CN104367600A (en) * | 2013-08-13 | 2015-02-25 | 财团法人工业技术研究院 | Application of Antrodia camphorata extract in preparing medicine for regulating Th17 cells or treating diseases related to Th17 cell regulation |
Non-Patent Citations (1)
| Title |
|---|
| MYERS JM等: "Cardiac myosin-Th17 responses promote heart failure in hunman myocarditis", 《JCI INSIGHT》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021218974A1 (en) * | 2020-04-28 | 2021-11-04 | Alps Biotech Co., Ltd. | Uses of antrodia cinnamomea extract in manufacturing products for reducing expression and treating associated diseases of angiotensin converting enzyme 2 |
| CN115697364A (en) * | 2020-04-28 | 2023-02-03 | 浩峰生物科技股份有限公司 | Application of Antrodia camphorata extract in preparation of products for reducing expression of angiotensin converting enzyme 2 and treating related diseases thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| TW201803577A (en) | 2018-02-01 |
| TWI629991B (en) | 2018-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kassim et al. | Catecholamine-induced cardiomyopathy | |
| US10583103B2 (en) | Method of treating heart failure with preserved ejection fraction with probenecid | |
| Li et al. | Inhibition of Rho-kinase ameliorates myocardial remodeling and fibrosis in pressure overload and myocardial infarction: Role of TGF-β1–TAK1 | |
| Kumar et al. | Catecholamine-induced cardiomyopathy: an endocrinologist’s perspective | |
| Weng et al. | Pleiotropic effects of myocardial MMP-9 inhibition to prevent ventricular arrhythmia | |
| Caziuc et al. | Stem cells improve the quality of colonic anastomoses-A systematic review | |
| Li et al. | Zerumbone, a humulane sesquiterpene from Syringa pinnatifolia, attenuates cardiac fibrosis by inhibiting of the TGF-β1/Smad signaling pathway after myocardial infarction in mice | |
| Stansfield et al. | Characterization of a model to independently study regression of ventricular hypertrophy | |
| Ma et al. | Isoproterenol increases left atrial fibrosis and susceptibility to atrial fibrillation by inducing atrial ischemic infarction in rats | |
| CN101618032B (en) | Application of sodium houttuyfonate in preparing medicament for preventing and treating myocardial hypertrophy and/or ventricular hypertrophy | |
| Yu et al. | Linggui Zhugan Decoction activates the SIRT1-AMPK-PGC1α signaling pathway to improve mitochondrial and oxidative damage in rats with chronic heart failure caused by myocardial infarction | |
| Tamayo et al. | Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure | |
| Fenner et al. | Inhibition of small-conductance calcium-activated potassium current (IK, Ca) leads to differential atrial electrophysiological effects in a horse model of persistent atrial fibrillation | |
| Linz et al. | Pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut reduces atrial fibrillation susceptibility in obese spontaneously hypertensive rats | |
| CN107648282A (en) | Application of the Antrodia camphorata in preventing and treating myocardial hypertrophy and myocardial fibrosis | |
| CN103720709A (en) | Cell apoptosis inducer containing chlorine dioxide and application thereof to preparation of cosmetics, or anti-aging or antineoplastic drugs | |
| US20170266253A1 (en) | Antithetical regulation of endothelial ace and ace2 by brg1-foxm1 complex underlies pathological cardiac hypertrophy | |
| Fiordaliso et al. | Effect of β-adrenergic and renin–angiotensin system blockade on myocyte apoptosis and oxidative stress in diabetic hypertensive rats | |
| Lv et al. | Effect of WenXin KeLi on Improvement of Arrhythmia after Myocardial Infarction by Intervening PI3K‐AKT‐mTOR Autophagy Pathway | |
| CN110511266A (en) | A kind of micromolecule polypeptide and application thereof | |
| Eshraghi et al. | Circular RNAs: a small piece in the heart failure puzzle | |
| Accardi et al. | Rat cardiovascular telemetry: Marginal distribution applied to positive control drugs | |
| Qiu et al. | BAOXIN granules protected mouse model with elevated afterload from cardiac hypertrophy by suppressing both inflammatory reaction and collagen deposition | |
| Lu et al. | Olmesartan medoxomil reverses glomerulosclerosis in renal tissue induced by myocardial infarction without changes in renal function | |
| CN107715111A (en) | Anti-cicatrix externally used preparation using Angiotensin-Converting class medicine as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180202 |
|
| RJ01 | Rejection of invention patent application after publication |